BMS Spins Off Mead Johnson In IPO, Retaining Majority Control
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb will spin off its Mead Johnson infants and children nutritional products business in an initial public offering of shares rather than sell the unit, the firm says
You may also be interested in...
“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position about the potential divestiture of the company’s non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.
“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position about the potential divestiture of the company’s non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.
“Likely” Merck Consumer-Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position regarding the potential divestiture of non-pharma assets, including the firm’s consumer-health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.